Press Releases Acelyrin, Inc.

Equities

SLRN

US00445A1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
4.88 ^USD	+1.88%		+14.82%	-34.58%

02:00pm	Acelyrin, Inc. Announces Leadership Transition	CI
Apr. 05	North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ACELYRIN, INC. Announces Leadership Transition	08:01am	GL
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones	08:01am	GL
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024	Apr. 29	GL
Affibody publishes Annual Report 2023	Apr. 19	AQ
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights	Mar. 28	GL
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights	Mar. 28	AQ
Acelyrin : Corporate Presentation	Mar. 20	PU
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	Mar. 20	GL
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	Mar. 20	AQ
Affibody’s Partner ACELYRIN Announces Positive Top-line Results for Izokibep in Psoriatic Arthritis and Long-Term Clinical Benefits in Hidradenitis Suppurativa	Mar. 11	AQ
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis	Mar. 11	GL
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis	Mar. 11	AQ
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients	Mar. 11	GL
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications	Feb. 15	GL
Levi & Korsinsky Notifies Acelyrin, Inc.(SLRN) Investors of a Class Action Lawsuit and Upcoming Deadline	Jan. 16	PR
FINAL SLRN DEADLINE: Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	Jan. 15	PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acelyrin, Inc. of Class Action Lawsuit and Upcoming Deadline - SLRN	Jan. 14	PR
SLRN Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Acelyrin, Inc. (SLRN) of Deadline in Securities Fraud Class Action Lawsuit	Jan. 12	PR
The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)	Jan. 12	PR
SLRN Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	Jan. 11	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Acelyrin, Inc.

Equities

SLRN

US00445A1007

Press Releases

Filters